Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus dose-escalation tolerability study in metastatic breast cancer
2014-005126-35Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoints: First episode of mucositis/stomatitis grade 2-4 and Cumulative rate of mucositis/stomatitis grade 2-4 at 12 weeks. Started Mar 2015; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-005126-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005126-35.